Clinical Trials Logo
  1. Home
  2. Allergies
  3. NCT00453583
  4. Details
NCT00453583 Clinical Trial

Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine

Allergies Clinical Trial

Official title:
Evaluation of the Treatment Satisfaction in Children Suffering From an Allergy and Who Received an Antihistamine Treatment

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00453583
Other study ID # A00420
Secondary ID
Status Completed
Phase N/A
First received March 28, 2007
Last updated December 13, 2013
Start date March 2007
Est. completion date January 2008

Study information
Verified date May 2012
Source UCB Pharma
Contact n/a
Is FDA regulated No
Health authority European Union: European Medicines AgencySouth Korea: Korea Food and Drug Administration (KFDA)India: Ministry of HealthMexico: National Institute of Public Health, Health SecretariatSpain: Spanish Agency of Medicines
Study type Observational

Clinical Trial Summary

This is a non-interventional retrospective data collection study from children aged from 2 to 12 years old diagnosed with an allergy and who received a treatment consisting of an H1-antihistamine. The period of last taken medication will be observed to evaluate the global satisfaction of the parents and physician for this last treatment.

Recruitment information / eligibility
Status Completed
Enrollment 4581
Est. completion date January 2008
Est. primary completion date January 2008
Accepts healthy volunteers No
Gender Both
Age group 2 Years to 12 Years
Eligibility Inclusion Criteria:

- Children from 2-12 included

- History of allergy

- Used an Antihistamine within market authorization

Exclusion Criteria:

- Child not yet treated for the presented allergy

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

Locations
Country Name City State
United States UCB Pharma Smyrna Georgia

Sponsors (1)
Lead Sponsor Collaborator
UCB Pharma

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Parent satisfaction on a 11-point scale duration of the study No
Secondary Physician satisfaction on an 11-point scale duration of the study No
Secondary Efficacy, tolerability and global satisfaction duration of the study No
See also
  Status Clinical Trial Phase
Completed NCT01612936 - T Cell Effector and Regulatory Mechanisms in Asthma Phase 1
Completed NCT00779116 - Multi-center, Pediatric, Open-label, Preference Study of Desloratadine 2.5 mg Reditab (SCH34117) and Zyrtec 5.0 mg Chewable Tablet Medications (Study P04574)(COMPLETED) Phase 4
Recruiting NCT06002685 - Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention N/A
Completed NCT04644783 - Novel Blood Test to Predict Safe Foods for Infants and Toddlers With Food Protein-induced Enterocolitis Syndrome (FPIES) N/A
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed NCT01454505 - Safety and Efficacy of AL-53817 Nasal Spray Solution Phase 1
Completed NCT01792232 - Effects of Co-Exposure to Air Pollution and Allergen N/A
Completed NCT00800332 - Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy Phase 2
Terminated NCT04641000 - The Alberta BLOOM Long Term Follow Up Study
Recruiting NCT05119868 - Effects of the Mediterranean Diet During Pregnancy on the Onset of Allergies in the Offspring N/A
Completed NCT00801502 - Salmon in Pregnancy Study N/A
Unknown status NCT00892684 - Does Omega-3 Fatty Acid Supplementation in Pregnancy and During Lactation Protect the Child From Allergic Disease? N/A
Completed NCT00700726 - Cohort Study of the Patterns of Microvesicles in the Serum of Participants With Atopic and Non-atopic Asthma N/A
Recruiting NCT00350376 - Impact of Asthma Treatments on Daily Activities N/A
Completed NCT00881634 - To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions Phase 1
Completed NCT00881127 - To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions Phase 1
Completed NCT03106493 - Upstate New York Infant Development Screening Program
Completed NCT02017431 - Air Pollution and Allergens - Attenuation of Health Effects Particle Reduction N/A
Completed NCT01711593 - Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma Phase 1
Completed NCT01529437 - Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies Phase 1

External Links